Today: 20 May 2026
Lloyds share price edges lower as buyback rolls on and UK rates loom
27 February 2026
1 min read

Lloyds share price edges lower as buyback rolls on and UK rates loom

London, Feb 27, 2026, 09:07 GMT — Regular session

  • Lloyds edged 0.1% lower shortly after the London open.
  • Bank reported buying back 8 million shares on Feb 26
  • UK rates and policy cues for March are under traders’ scrutiny.

Lloyds Banking Group plc (LLOY.L) edged down 0.1% to 104.8 pence in early London trading on Friday. The move, though slight, follows the latest buyback update and keeps the spotlight on the lender’s shares. The stock started at 104.2 pence, with trades so far ranging from 103.65 up to 104.9 pence.

Why it’s in focus: Lloyds leans hard on the UK market, so its profits often rise or fall with local interest rates and how busy the mortgage business gets. Capital returns are a big piece here as well; buybacks boost EPS by cutting the number of shares out there, even in stretches when top-line growth is spotty.

Lloyds picked up 8 million ordinary shares on Thursday, according to a regulatory filing, paying a volume-weighted average of 104.4873 pence apiece. Prices spanned from 104.05 to 104.95 pence. Goldman Sachs International was the seller. The group plans to cancel the shares.

The buyback comes as part of a broader capital-return package detailed with full-year numbers at the end of last month. Lloyds showed a 12% increase in 2025 pretax profit, hitting 6.7 billion pounds, and rolled out a 1.75 billion-pound buyback. The bank also upped its profitability target, now aiming for return on tangible equity north of 16% by 2026. “Ongoing strategic execution and momentum,” is how CEO Charlie Nunn summed up the results. Reuters

UK stocks pushed to fresh highs on Thursday, lifted by strong performances from major names and ongoing hopes for stable rate cuts. “It is likely that the UK index’s outperformance is here to stay,” said Axel Rudolph, senior financial analyst at IG, highlighting the market’s lower valuations relative to tech-heavy U.S. counterparts. Reuters

UK bank stocks edged lower, with Barclays sliding at the open after The Times flagged possible losses tied to the collapse of mortgage provider Market Financial Solutions. Citi analysts said the headline exposure “may warrant some caution,” but stressed that arranging a loan isn’t the same as carrying the risk on Barclays’ own books. Reuters

Lloyds notified investors that its UK shares go ex-dividend on April 9, so anyone picking them up after that date won’t receive the next payout. The final 2025 dividend lands on May 19.

Still, buybacks don’t always provide steady support—if rates move unexpectedly, that cushion can disappear in a hurry. Quick rate cuts tend to pinch net interest margin, the difference between what banks take in from loans and what they shell out for deposits. And if the housing market softens, lending growth and credit quality can take a hit, too.

Coming Tuesday, March 3, Chancellor Rachel Reeves will unveil revised economic forecasts. The UK Debt Management Office also updates its debt issuance plans that day—both of which can shift gilt yields and, with them, UK bank valuations.

Stock Market Today

  • Sensex, Nifty likely to open lower amid rising oil prices and geopolitical tensions
    May 19, 2026, 11:45 PM EDT. Indian stock markets are expected to open lower on Wednesday due to rising oil prices, higher U.S. bond yields, and renewed geopolitical tensions stemming from the Iran conflict. Nifty futures indicated a cautious start below Tuesday's close, with analysts citing weak global cues and investor concerns over inflation and global uncertainty. Foreign institutional investors remained net sellers, offloading Rs 2,457 crore of Indian shares amid persistent outflows totaling nearly USD 23 billion this year. Elevated crude prices, fueled by ongoing Middle East tensions, pose inflation risks and pressure the rupee. Investors will focus on quarterly corporate earnings amid continued market volatility, as Nifty50 trades within a weak range between 23,300 and 23,800 points.

Latest articles

Wall Street Hit by Yield Jolt With Nvidia Up Next

Wall Street Hit by Yield Jolt With Nvidia Up Next

20 May 2026
U.S. stock ETFs remained lower late Tuesday after Wall Street’s main indexes fell for a third straight session, pressured by rising Treasury yields and caution ahead of Nvidia’s earnings. The SPDR S&P 500 ETF dropped 0.7% to $733.73. The 10-year Treasury yield hit 4.687%, its highest since January 2025, before easing. Nvidia shares slipped 0.7% after hours, with traders bracing for a major move post-earnings.
Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

20 May 2026
Viavi Solutions shares dropped 7.1% in after-hours trading Tuesday after the company announced a $500 million public stock offering aimed at repaying debt. The offering, unveiled just after the Nasdaq close, could add roughly 10.1 million new shares. Viavi plans to use proceeds to pay down a $450 million loan. Total debt would fall to $650 million, according to a preliminary SEC filing.
Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

20 May 2026
Analog Devices agreed to acquire Empower Semiconductor for $1.5 billion in cash, sending ADI shares up 1.36% to $419.95 in after-hours trading after closing down 1.02%. The deal, approved by both boards, is expected to close in the second half of 2026 pending regulatory review. Empower CEO Tim Phillips will continue to lead integrated voltage regulator work after the merger.
Vertiv (VRT) stock price dips from record as AI valuation worries bite again
Previous Story

Vertiv (VRT) stock price dips from record as AI valuation worries bite again

GSK share price today: stock edges up after Japan and China reviews, plus $950 million 35Pharma deal
Next Story

GSK share price today: stock edges up after Japan and China reviews, plus $950 million 35Pharma deal

Go toTop